Disclosure: We may earn a commission if you buy through links on this page — at no extra cost to you. Learn more.
Statements on this site have not been evaluated by the Food and Drug Administration.
Products and information are not intended to diagnose, treat, cure, or prevent any disease. Learn More
Products and information are not intended to diagnose, treat, cure, or prevent any disease. Learn More
Summary
Saccharomyces boulardii is a probiotic yeast used to support GI resilience, especially during or after antibiotic use and in infectious or travel‑related diarrhea. Human RCTs support reductions in diarrhea incidence and duration, with emerging signals for stress‑related GI symptom relief.
Mental Clarity, Focus, and Energy
- Indirect effects: Any improvements in focus or energy are secondary to better GI comfort and reduced illness‑related fatigue.
Brain Health
- Mechanisms: Modulates pathogen adhesion and toxin binding, supports IgA and barrier function, and tempers inflammatory signaling.
- Cognition‑specific human data are limited; benefits are GI‑first.
Gut Health
- Strongest evidence: prevention and treatment of antibiotic‑associated diarrhea (AAD) and acute infectious diarrhea; helpful adjunct in traveler’s diarrhea.
- Typical doses are 5–10 billion CFU/day; benefits often appear within days in acute settings.
Brain-Gut Axis
- By reducing inflammation and restoring barrier function during GI stress, S. boulardii may lower pro‑inflammatory gut–brain signaling and indirectly support mood and stress resilience.
Evidence Summary
Benefit Area | Evidence Quality | Effect Noted | Notes |
Mental Clarity | Limited | Indirect via GI recovery | Secondary benefit |
Focus Enhancement | Limited | Improved daytime function | When GI symptoms improve |
Energy Support | Limited | Reduced illness‑related fatigue | Adjunctive role |
Brain Health | Limited–Emerging | Lower inflammatory signaling (indirect) | GI‑focused trials |
Gut Health | Moderate–Strong | Prevents/shortens diarrhea episodes | 5–10B CFU/day |
Brain–Gut Optimization | Emerging | Barrier and immune support | Indirect evidence |
Typical Dosing Instructions
- Standard dose: 5–10 billion CFU/day; in acute diarrhea follow product/clinician guidance for higher short‑term dosing
- Timing: With meals; separate from systemic antifungals
- Form: Capsule or powder with verified CFU at end of shelf life
- Notes: Continue during antibiotic course and for 1–2 weeks after, spacing 2+ hours from antibiotic doses
Safety Considerations
- General safety: Generally well tolerated in healthy adults
- Common effects: Transient gas/bloating
- Contraindications and cautions: Use caution if immunocompromised or with central venous catheters due to rare fungemia reports; separate from systemic antifungals
- Populations: Limited pregnancy data; consult clinician for use during pregnancy
- Monitoring: Track stool frequency, consistency, and GI symptoms; discontinue if adverse effects persist
References
- Systematic review with meta‑analysis: Saccharomyces boulardii in the prevention of antibiotic‑associated diarrhoea, Alimentary Pharmacology & Therapeutics, 2015-01-01
- Meta‑analysis: non‑pathogenic yeast Saccharomyces boulardii in the prevention of antibiotic‑associated diarrhoea, Alimentary Pharmacology & Therapeutics, 2005-08-26
- Probiotics for the Prevention of Antibiotic‑associated Diarrhea in Adults: A Meta‑Analysis of Randomized Placebo‑Controlled Trials, Gastroenterology Research and Practice, 2020-11-23
- Saccharomyces boulardii to Prevent Antibiotic‑Associated Diarrhea: A Randomized, Double‑Masked, Placebo‑Controlled Trial, Open Forum Infectious Diseases, 2016-01-29